Steven E Nissen Md - Athlete Stats Center

Steven E Nissen Md - Athlete Stats Center Information Guide

  1. Background to Steven E Nissen Md - Athlete Stats Center
  2. Important Facts
  3. History
  4. Full Guide
  5. Future Outlook

Background to Steven E Nissen Md - Athlete Stats Center

Player Profile Cardiologist Steven Nissen, MD
Looking for Steven E Nissen Md - Athlete Stats Center? We've gathered the latest player statistics, match history, rankings, and performance insights for Steven E Nissen Md - Athlete Stats Center. Check the complete Player Profile and career overview.

Heart disease remains the killer worldwide, but are we doing enough to prevent it?* In this episode of The Ultimate Asset, LIVESTREAM RECORDING February 14, 2019 Lipoprotein(a) in Coronary Disease: An Emerging Novel Target” Houston ... NYACC is proud to present the next installment in its After Shocks series, sessions that provide bite-sized recaps of high-impact ... Lipoprotein(a) in Coronary Disease: An Emerging Novel Target” Houston Methodist Hospital, William A. Zoghbi, Tirzepatide treatment resulted in a substantial reduction in a broad 6-component composite of cardiovascular and kidney ... We would love to hear your thoughts on the episodes! (

Effects of Tirzepatide Compared With Dulaglutide on Expanded Cardiorenal Outcomes.

Important Facts

Career Overview ObesityWeek 2018 Keynote: Steven E. Nissen, MD
Explore the primary sources for Steven E Nissen Md - Athlete Stats Center.

History

Sports Performance Reversing Heart Disease: The Science of LDL and Lipoprotein(a) // Dr. Steven Nissen
Stay updated on Steven E Nissen Md - Athlete Stats Center's newest achievements.

Lipoprotein(a) in Coronary Disease: An Emerging Novel Target (Steven E Nissen, MD) February 14, 2019
"After Shocks" with Steven E. Nissen, MD, MACC, and Eugenia Gianos, MD, FACC
Grand Rounds Interview with Steven E. Nissen, MD (February 14, 2019)
Tirzepatide Outperforms Dulaglutide in Cardiorenal Outcomes, With Steven Nissen, MD
AHA 2019: Highlights with Dr. Nissen
Lp(a): a basic clinical approach with Dr. Steven Nissen Part 1 of 2
Steven Nissen, MD: Cholesterol Guidelines
Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: Bempedoic Acid And Cardiovascular Outcomes
From Trial to Pract: Dr. Nissen on the cardiorenal benefits of SURPASS-CVOT

Full Guide

Data is compiled from public records and verified media reports.

Last Updated: August 24, 2026

Future Outlook

Sports Performance Professor Steven Nissen - Lipoprotein(a): a new target for therapeutic intervention
For 2026, Steven E Nissen Md - Athlete Stats Center remains one of the most talked-about professional athlete profiles. Check back for the newest reports.

Disclaimer: Disclaimer: All {Player Profile|Athlete Statistics|Sports Record|Performance Profile|Match Statistics|Sports Database} information, player statistics, rankings, and performance data are compiled from publicly available sports databases, official league records, and trusted third-party sources.

Related Celebrity Net Worths

Cardiologist Steven Nissen, MD net worth ObesityWeek 2018 Keynote: Steven E. Nissen, MD net worth Reversing Heart Disease: The Science of LDL and Lipoprotein(a) // Dr. Steven Nissen net worth Professor Steven Nissen - Lipoprotein(a): a new target for therapeutic intervention net worth Lipoprotein(a) in Coronary Disease: An Emerging Novel Target (Steven E Nissen, MD) February 14, 2019 net worth "After Shocks" with Steven E. Nissen, MD, MACC, and Eugenia Gianos, MD, FACC net worth Grand Rounds Interview with Steven E. Nissen, MD (February 14, 2019) net worth Tirzepatide Outperforms Dulaglutide in Cardiorenal Outcomes, With Steven Nissen, MD net worth Gmc Elevation Towing Capacity net worth 1996 Gmc Sierra Custom net worth 1999 Gmc Sonoma Headlights net worth Dorais Chevrolet Gmc Wabash Vehicles net worth Johnson City Gmc Dealer net worth Best Leveling Kit For Gmc Sierra 1500 net worth 2008 Gmc Acadia Transmission Filter Location net worth Gmc Acadia In Snow net worth
Cardiologist Steven Nissen, MD

Cardiologist Steven Nissen, MD

Estimated Net Worth: | Estimated Worth: $4M - $42M

To learn more about Cleveland Clinic's

View Profile
ObesityWeek 2018 Keynote: Steven E. Nissen, MD

ObesityWeek 2018 Keynote: Steven E. Nissen, MD

Estimated Net Worth: | Estimated Worth: $24M - $42M

Steven E

View Profile
Reversing Heart Disease: The Science of LDL and Lipoprotein(a) // Dr. Steven Nissen

Reversing Heart Disease: The Science of LDL and Lipoprotein(a) // Dr. Steven Nissen

Estimated Net Worth: | Estimated Worth: $23M - $30M

Heart disease remains the #1 killer worldwide, but are we doing enough to prevent it?* In this episode of The Ultimate Asset,

View Profile
Professor Steven Nissen - Lipoprotein(a): a new target for therapeutic intervention

Professor Steven Nissen - Lipoprotein(a): a new target for therapeutic intervention

Estimated Net Worth: | Estimated Worth: $41M - $66M

Professor

View Profile
Lipoprotein(a) in Coronary Disease: An Emerging Novel Target (Steven E Nissen, MD) February 14, 2019

Lipoprotein(a) in Coronary Disease: An Emerging Novel Target (Steven E Nissen, MD) February 14, 2019

Estimated Net Worth: | Estimated Worth: $19M - $52M

LIVESTREAM RECORDING February 14, 2019 Lipoprotein(a) in Coronary Disease: An Emerging Novel Target” Houston ...

View Profile
"After Shocks" with Steven E. Nissen, MD, MACC, and Eugenia Gianos, MD, FACC

"After Shocks" with Steven E. Nissen, MD, MACC, and Eugenia Gianos, MD, FACC

Estimated Net Worth: | Estimated Worth: $65M - $74M

NYACC is proud to present the next installment in its After Shocks series, sessions that provide bite-sized recaps of high-impact ...

View Profile
Grand Rounds Interview with Steven E. Nissen, MD (February 14, 2019)

Grand Rounds Interview with Steven E. Nissen, MD (February 14, 2019)

Estimated Net Worth: | Estimated Worth: $8M - $30M

Lipoprotein(a) in Coronary Disease: An Emerging Novel Target” Houston Methodist Hospital, William A. Zoghbi,

View Profile
Tirzepatide Outperforms Dulaglutide in Cardiorenal Outcomes, With Steven Nissen, MD

Tirzepatide Outperforms Dulaglutide in Cardiorenal Outcomes, With Steven Nissen, MD

Estimated Net Worth: | Estimated Worth: $23M - $40M

Tirzepatide treatment resulted in a substantial reduction in a broad 6-component composite of cardiovascular and kidney ...

View Profile
AHA 2019: Highlights with Dr. Nissen

AHA 2019: Highlights with Dr. Nissen

Estimated Net Worth: | Estimated Worth: $33M - $40M

Dr

View Profile
Lp(a): a basic clinical approach with Dr. Steven Nissen Part 1 of 2

Lp(a): a basic clinical approach with Dr. Steven Nissen Part 1 of 2

Estimated Net Worth: | Estimated Worth: $82M - $108M

We would love to hear your thoughts on the episodes! (https://www.buzzsprout.com/1952816/fan_mail/new)

View Profile
Steven Nissen, MD: Cholesterol Guidelines

Steven Nissen, MD: Cholesterol Guidelines

Estimated Net Worth: | Estimated Worth: $86M - $116M

Steven Nissen

View Profile
From Trial to Pract: Dr. Nissen on  the cardiorenal benefits of SURPASS-CVOT

From Trial to Pract: Dr. Nissen on the cardiorenal benefits of SURPASS-CVOT

Estimated Net Worth: | Estimated Worth: $59M - $82M

Effects of Tirzepatide Compared With Dulaglutide on Expanded Cardiorenal Outcomes.

View Profile